Can Trulicity Be Used with Insulin?
Yes, Trulicity (dulaglutide), a GLP-1 receptor agonist for type 2 diabetes, can be used with insulin. Clinical studies and prescribing information support this combination to improve glycemic control when insulin alone is insufficient.[1][2]
How Is It Typically Combined?
Trulicity is often added to basal insulin like insulin glargine (Lantus) or degludec (Tresiba). In trials, patients on Trulicity plus insulin saw greater A1C reductions than insulin alone, with starting doses adjusted to minimize lows.[1] Mealtime (bolus) insulin can also pair with it, but total insulin dose often drops by 10-20% to avoid hypoglycemia.[2]
What Do Clinical Trials Show?
The AWARD-4 trial tested Trulicity with insulin glargine: after 52 weeks, Trulicity 1.5 mg plus glargine lowered A1C by 1.9% versus 1.4% with glargine alone. Weight loss averaged 1.3 kg with the combo, unlike weight gain on insulin solo.[1] Similar results held in head-to-head studies against other GLP-1s like exenatide.
Hypoglycemia Risk and Monitoring
Combining raises hypoglycemia odds, especially with sulfonylureas or high insulin doses. Trulicity's label warns of severe lows; start low and titrate insulin slowly while monitoring blood glucose frequently.[2] Symptoms include shakiness, sweating, or confusion—treat with fast carbs.
Prescribing Guidelines
ADA and EASD recommend GLP-1s like Trulicity with insulin for type 2 diabetes not at goal on basal insulin. Avoid in type 1 diabetes or diabetic ketoacidosis. Dose: Trulicity weekly (0.75-4.5 mg); adjust insulin per response.[3]
Patient Experiences and Side Effects
Users report better control and less insulin needs, but nausea (common early with Trulicity) or injection site issues occur. Pancreatitis risk is low but monitored; thyroid tumor warnings apply.[2] Consult a doctor for personalization.
[1] https://www.trulicity.com/hcp (Eli Lilly prescribing info and AWARD trials)
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/125469s030lbl.pdf (FDA label)
[3] https://diabetesjournals.org/care/issue/46/Supplement1 (ADA Standards of Care 2023)